A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciaf346 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Phyo Pyae Nyein und 26 weiteren Autor:innen. Beteiligte Einrichtung: The Kirby Institute, University of New South Wales, Sydney, Australia. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, HIV Infections, Darunavir, HIV-1. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: UNITAID, National Institute of Allergy and Infectious Diseases, NIH HHS.
Abstract (Originalsprache)
Background
Longer-term outcome data following second-line antiretroviral therapy initiation in resource-limited settings is limited, especially in regions where genotypic resistance is inaccessible. This analysis evaluated extended efficacy and tolerability data from the D2EFT study.
Methods
D2EFT is a completed, multicenter, phase IIIB/IV, randomized, open-label trial in 14 low- and middle-income countries. People with human immunodeficiency virus (HIV) who had failed first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens were switched to 1 of ritonavir-boosted darunavir plus 2 nucleoside reverse transcriptase inhibitors (DRV/r + 2NRTIs), ritonavir-boosted darunavir plus dolutegravir (DTG + DRV/r), or dolutegravir with tenofovir disoproxil fumarate plus either lamivudine or emtricitabine (DTG + TDF/XTC), with or without pre-switch genotyping. Here we report virological suppression at 96 weeks, defined as HIV RNA <50 copies/mL in a modified intention-to-treat population.
Results
Between November 2017 and January 2022, 1190 participants were screened, 828 were randomized, and 826 were included in the analysis. At week 96, the proportions of participants with HIV RNA <50 copies/mL were 191/251 (76.1%) in DRV/r + 2NRTIs, 215/251 (85.7%) in DTG + DRV/r, and 231/283 (81.6%) in DTG + TDF/XTC. The treatment differences (95% confidence intervals [CIs]) in proportions achieving virological suppression were 9.6% (2.7, 16.4) in DTG + DRV/r and 9.0% (1.4, 16.6) in DTG + TDF/XTC, compared to DRV/r + 2NRTIs. Intermediate or high-level dolutegravir resistance was identified in 3/27 (13%) of virological failures in individuals taking DTG + TDF/XTC but in no one taking DTG + DRV/r. No darunavir resistance was observed.
Conclusions
After 96 weeks of follow-up, DTG + DRV/r and DTG + TDF/XTC demonstrated virological superiority over DRV/r + 2NRTIs after first-line NNRTI-failure. However, emerging dolutegravir resistance, which was observed only in individuals taking DTG + TDF/XTC, requires ongoing global surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Kirby Institute, University of New South Wales, Sydney, Australia.
- Department of Internal Medicine, Faculty of Medicine and Health Sciences, University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe.
- International Research Center of Excellence (IRCE), Institute of Human Virology Nigeria, Abuja, Nigeria.
- Desmond Tutu Health Foundation, Cape Town, South Africa.
- Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS) Voluntary Health Services (VHS), Chennai, India.
- HIV-NAT, Thai Red Cross AIDS and Infectious Disease Research Centre, and Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
ORCID-Profile: Phyo Pyae Nyein, Anchalee Avihingsanon, Mohamed Cisse, Jaime F Andrade Villanueva, Evy Yunihastuti, Josh Hanson, Gail V Matthews
Förderung
- UNITAID
- National Institute of Allergy and Infectious Diseases
- NIH HHS
- National Health and Medical Research Council, Australia
- ViiV Healthcare
- Janssen Pharmaceutica
- National Institutes of Health
Zitieren
APA
Nyein, P. P., Borok, M., Eriobu, N., Kaplan, R., Kumarasamy, N., Avihingsanon, A., Losso, M. H., Azwa, I., Karyana, M., Dao, S., Cisse, M., Andrade Villanueva, J. F., Lupo, S., Cardoso, S. W., Yunihastuti, E., Subronto, Y. W., Fitriah, M., Katu, S., Brown, D., …, & D2EFT Study Team (2026). A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf346
Vancouver
Nyein PP, Borok M, Eriobu N, Kaplan R, Kumarasamy N, Avihingsanon A, et al. A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf346
BibTeX
@article{Nyein2026,
author = {Nyein, Phyo Pyae and Borok, Margaret and Eriobu, Nnakelu and Kaplan, Richard and Kumarasamy, Nagalingeswaran and Avihingsanon, Anchalee and Losso, Marcelo H and Azwa, Iskandar and Karyana, Muhammad and Dao, Sounkalo and Cisse, Mohamed and Andrade Villanueva, Jaime F and Lupo, Sergio and Cardoso, Sandra Wagner and Yunihastuti, Evy and Subronto, Yanri Wijayanti and Fitriah, Munawaroh and Katu, Sudirman and Brown, Dannae and Papot, Emmanuelle and Hutchinson, Jolie and Kelleher, Anthony and Hanson, Josh and Dharan, Nila J and Petoumenos, Kathy and Matthews, Gail V and D2EFT Study Team, D2EFT Study Team},
title = {A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciaf346}
}
EUVIMED